Abatacept Approved for Adult PsA

The safety profiles of these trials were comparable to rheumatoid arthritis (RA) safety trials. The most serious adverse events in adult RA studies were serious infections and malignancies. In the PsA-II trial, the most common adverse events were bronchitis, nasopharyngitis and upper respiratory tract infections.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

U.S. Food and Drug Administration. Letter: Bristol Myers Squibb supplemental approval letter. 2017 Jun 30.
Bristol-Myers Squibb Co. News release: Bristol-Myers Squibb’s Orencia (abatacept) receives FDA approval for treatment of active psoriatic arthritis (PsA) in adults. 2017 Jul 6.

PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…

A 36-year-old woman presented at the Johns Hopkins Arthritis Center for a second opinion regarding a diagnosis of psoriatic arthritis (PsA). One year prior to our evaluation, she had developed pain and stiffness in her hands, feet, knees, ankles, elbows and shoulders. She had mild plaque psoriasis of the scalp and base of the neck,…

Abatacept Approved for Adult PsA On June 30, the U.S. Food and Drug Administration (FDA) approved abatacept (Orencia) to treat adults with active psoriatic arthritis (PsA).1 Abatacept is available as both an intravenous formulation and a subcutaneous injection.2 The approval was based on results of two randomized, double-blind, placebo-controlled trials, PsA-I and PsA-II, during which…

Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…

Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022

Case Report: A Psoriatic Arthritis Patient with Dactylitis & Enthesitis

Abatacept Approved for Psoriatic Arthritis in Adults; Sirukumab Approval Stalls

Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis

Related Articles